Hepatitis Monthly

Published by: Kowsar

Study the Cross-talk Between Hepatitis B Virus Infection and Interferon Regulatory Factors in Liver Transplant Patients

Sahar Janfeshan 1 , Ramin Yaghobi 2 , * , Akram Eidi 1 , Mohammad Hossein Karimi 2 , Bita Geramizadeh 2 , Seyed Ali Malekhosseini 3 and Farshid Kafilzadeh 4
Authors Information
1 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, IR Iran
2 Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Transplant Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, IR Iran
Article information
  • Hepatitis Monthly: November 2017, 17 (11); e12426
  • Published Online: October 28, 2017
  • Article Type: Research Article
  • Received: October 24, 2016
  • Revised: May 2, 2017
  • Accepted: October 7, 2017
  • DOI: 10.5812/hepatmon.12426

To Cite: Janfeshan S, Yaghobi R, Eidi A, Karimi M H, Geramizadeh B, et al. Study the Cross-talk Between Hepatitis B Virus Infection and Interferon Regulatory Factors in Liver Transplant Patients, Hepat Mon. 2017 ;17(11):e12426. doi: 10.5812/hepatmon.12426.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012; 4(3)[DOI][PubMed]
  • 2. Barker CE, Ali S, O'Boyle G, Kirby JA. Transplantation and inflammation: implications for the modification of chemokine function. Immunology. 2014; 143(2): 138-45[DOI][PubMed]
  • 3. Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol. 2013; 19(48): 9189-97[DOI][PubMed]
  • 4. Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. World J Gastroenterol. 2014; 20(39): 14142-55[DOI][PubMed]
  • 5. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther. 2006; 23(8): 1031-41[DOI][PubMed]
  • 6. Shakiba E, Yaghobi R, Ramzi M. Prevalence of viral infections and hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Exp Clin Transplant. 2011; 9(6): 405-12[PubMed]
  • 7. Mirzaee M, Yaghobi R, Ramzi M, Roshan Nia M. The prevalence of molecular and immunologic infective markers of hepatitis viruses in patients with hematological malignancies. Mol Biol Rep. 2012; 39(2): 1217-23[DOI][PubMed]
  • 8. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007; 27(4): 339-50[DOI][PubMed]
  • 9. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 2010; 59(4): 489-510[DOI][PubMed]
  • 10. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008; 26: 535-84[DOI][PubMed]
  • 11. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006; 6(9): 644-58[DOI][PubMed]
  • 12. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006; 72(11): 1469-76[DOI][PubMed]
  • 13. Paun A, Pitha PM. The IRF family, revisited. Biochimie. 2007; 89(6-7): 744-53[DOI][PubMed]
  • 14. Li Y, Hu X, Song Y, Lu Z, Ning T, Cai H, et al. Identification of novel alternative splicing variants of interferon regulatory factor 3. Biochim Biophys Acta. 2011; 1809(3): 166-75[DOI][PubMed]
  • 15. Marsili G, Perrotti E, Remoli AL, Acchioni C, Sgarbanti M, Battistini A. IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better. J Interferon Cytokine Res. 2016; 36(7): 414-32[DOI][PubMed]
  • 16. Chen W, Royer WJ. Structural insights into interferon regulatory factor activation. Cell Signal. 2010; 22(6): 883-7[DOI][PubMed]
  • 17. Battistini A. Interferon regulatory factors in immune cell development and host response to infections. 2012;
  • 18. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004; 279(35): 36570-8[DOI][PubMed]
  • 19. Vandevenne P, Lebrun M, El Mjiyad N, Ote I, Di Valentin E, Habraken Y, et al. The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS One. 2011; 6(2)[DOI][PubMed]
  • 20. van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, et al. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. PLoS Pathog. 2014; 10(2)[DOI][PubMed]
  • 21. Wang JT, Doong SL, Teng SC, Lee CP, Tsai CH, Chen MR. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J Virol. 2009; 83(4): 1856-69[DOI][PubMed]
  • 22. Lefort S, Soucy-Faulkner A, Grandvaux N, Flamand L. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J Virol. 2007; 81(20): 10950-60[DOI][PubMed]
  • 23. Bauhofer O, Summerfield A, Sakoda Y, Tratschin JD, Hofmann MA, Ruggli N. Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol. 2007; 81(7): 3087-96[DOI][PubMed]
  • 24. Seago J, Hilton L, Reid E, Doceul V, Jeyatheesan J, Moganeradj K, et al. The Npro product of classical swine fever virus and bovine viral diarrhea virus uses a conserved mechanism to target interferon regulatory factor-3. J Gen Virol. 2007; 88: 3002-6[DOI][PubMed]
  • 25. Zare A, Karimi MH, Rashki A, Geramizadeh B, Afshari A, Miri HR, et al. Association of the Interleukin-27 Gene Expression and Hepatitis B Virus Infection in Liver Transplanted Patients. Exp Clin Transplant. 2017; 15(5): 554-60[DOI][PubMed]
  • 26. Afshari A, Yaghobi R, Karimi MH, Darbooie M, Azarpira N. Interleukin-17 gene expression and serum levels in acute rejected and non-rejected liver transplant patients. Iran J Immunol. 2014; 11(1): 29-39[PubMed]
  • 27. Janfeshan S, Yaghobi R, Eidi A, Karimi MH, Geramizadeh B, Malekhosseini SA, et al. Expression Profile of Interferon Regulatory Factor 1 in Chronic Hepatitis B Virus-Infected Liver Transplant Patients. Exp Clin Transplant. 2016; [DOI][PubMed]
  • 28. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol. 2009; 46(13): 2640-6[DOI][PubMed]
  • 29. Momeni M, Zainodini N, Bidaki R, Hassanshahi G, Daneshvar H, Khaleghinia M, et al. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Hum Immunol. 2014; 75(1): 15-9[DOI][PubMed]
  • 30. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One. 2011; 6(10)[DOI][PubMed]
  • 31. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 2010; 6(7)[DOI][PubMed]
  • 32. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol. 2010; 91: 2080-90[DOI][PubMed]
  • 33. Jiang J, Tang H. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell. 2010; 1(12): 1106-17[DOI][PubMed]
  • 34. Kreisel D, Goldstein DR. Innate immunity and organ transplantation: focus on lung transplantation. Transpl Int. 2013; 26(1): 2-10[DOI][PubMed]
  • 35. Afshari A, Yaghobi R, Karimi MH, Darbouy M, Azarpira N, Geramizadeh B, et al. IL-17 mRNA expression and cytomegalovirus infection in liver transplant patients. Exp Clin Transplant. 2015; 13 Suppl 1: 83-9[PubMed]
  • 36. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004; 101(17): 6669-74[DOI][PubMed]
  • 37. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79(15): 9369-80[DOI][PubMed]
  • 38. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A. 1996; 93(10): 4589-94[PubMed]
  • 39. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol. 2000; 74(9): 4165-73[PubMed]
  • 40. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4): 258-66[DOI][PubMed]
  • 41. Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014; 11: 22[DOI][PubMed]
  • 42. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 43. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iran Med. 2000; 3(4): 192-201
  • 44. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol. 2009; 83(2): 847-58[DOI][PubMed]
  • 45. Pei RJ, Chen XW, Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol. 2014; 20(33): 11618-29[DOI][PubMed]
  • 46. Zhai Y, Shen XD, O'Connell R, Gao F, Lassman C, Busuttil RW, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol. 2004; 173(12): 7115-9[PubMed]
  • 47. Testro AG, Visvanathan K, Skinner N, Markovska V, Crowley P, Angus PW, et al. Acute allograft rejection in human liver transplant recipients is associated with signaling through toll-like receptor 4. J Gastroenterol Hepatol. 2011; 26(1): 155-63[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments